WHAT IS CLAIMED IS:

1. ~~A regimen~~ Use of a vinorelbine compound in the manufacture of a medicament for treating a neoplasm in a subject, said ~~regimen~~ treatment further comprising administration of~~:~~

~~administering a vinorelbine compound; and~~

~~administering~~ a HKI-272 compound.

2. The ~~regimen~~ use according to claim 1, wherein the ~~administering~~ administration steps occur concurrently, sequentially, simultaneously, in a specified order, or according to a specific temporal relationship.

3. The ~~regimen~~ use according to claim 1, wherein said vinorelbine compound is administered in a unit dose.

4. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is administered in a unit dose.

5. The ~~regimen~~ use according to claim 1, wherein said vinorelbine compound is vinorelbine.

6. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is HKI-272.

7. The ~~regimen~~ use according to claim 1, wherein one or both of said vinorelbine compound and said HKI-272 compound are to be delivered intravenously to said subject.

8. The ~~regimen~~ use according to claim 1, wherein one or both of said vinorelbine compound and said HKI-272 compound are to be delivered orally to said subject.

9. The ~~regimen~~ use according to claim 1, wherein said neoplasm is associated with overexpression or amplification of HER-2.

10. The ~~regimen~~ use according to claim 1, wherein said neoplasm is metastatic.

11. The ~~regimen~~ use according to claim 1, wherein said neoplasm is selected from the group consisting of a lung cancer, breast cancer, myeloma, prostate cancer, head and neck cancer, transitional cell carcinoma, small cell neuroendocrine carcinoma of the uterine cervix, and large cell neuroendocrine carcinoma of the uterine cervix.

12. The ~~regimen~~ use according to claim 11, wherein said neoplasm is a breast cancer.

13. The ~~regimen~~ use according to claim 12, wherein said breast cancer is a metastatic, HER-2 -positive breast cancer.

14. The ~~regimen~~ use according to claim 1, wherein said neoplasm is an advanced solid tumor.

15. The ~~regimen~~ use according to claim 1, wherein said vinorelbine compound is to be administered in an amount of at least about 20 mg/L.

16. The ~~regimen~~ use according to claim 15, wherein said vinorelbine compound is to be administered in an amount of about 20 to about 25 mg/L.

17. The ~~regimen~~ use according to claim 16, wherein said vinorelbine compound is to be administered in an amount of about 25 mg/L.

18. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is to be administered in an amount of at least about 120 mg.

19. The ~~regimen~~ use according to claim 18, wherein said HKI-272 compound is to be administered in an amount of at least about 160 mg.

20. The ~~regimen~~ use according to claim 19, wherein said HKI-272 compound is to be administered in an amount of at least about 240 mg.

21. The ~~regimen~~ use according to claim 4, wherein said unit dose is a tablet.

22. The ~~regimen~~ use according to claim 1, wherein said HKI- 272 compound is to be administered daily.

23. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is to be administered at least once daily.

24. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is to be administered on day 1 of said regimen.

25. The ~~regimen~~ use according to claim 10, wherein said HKI-272 compound is to be administered on day 2 of said regimen.

26. The ~~regimen~~ use according to claim 1, wherein said HKI-272 compound is to be administered for at least 2 continuous weeks.

27. A pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable carrier.

28. The ~~regimen~~ use according to claim 1, further comprising radiation.